Journal list menu
IssueCancer Communications: Volume 41, Issue 1
1-87January 2021
Export Citations
Download PDFs
ISSUE INFORMATION
REVIEWS
Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?
- Pages: 3-15
- First Published: 02 December 2020
New insights into molecules and pathways of cancer metabolism and therapeutic implications
- Pages: 16-36
- First Published: 10 November 2020
ORIGINAL ARTICLES
Development and validation of a web-based calculator to predict individualized conditional risk of site-specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases
- Pages: 37-50
- First Published: 03 December 2020
All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling
- Pages: 51-61
- First Published: January 2021
The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells
- Pages: 62-78
- First Published: January 2021
LETTER TO THE EDITOR
CircBA1 derived from BCR-ABL fusion gene inhibits cell proliferation in chronic myeloid leukemia
- Pages: 79-82
- First Published: 14 January 2021
CASE REPORT
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
- Pages: 83-87
- First Published: 02 January 2021
Tepotinib have high retention in the tumor and sustained inhibition of MET and its downstream pathways. Tepotinib is a key drug for cancer patients with MET exon 14 skipping mutation. However, its bioavailability in the CSF in humans has not been elucidated. The blood brain barrier protects the CNS from toxicity, but also prevents therapeutic drugs from accessing the brain. We report a case of leptomeningeal metastasis successfully treated with tepotinib in a patient with poor PS and on the bioavailability of tepotinib in the CSF in humans.
Sign up for email alerts
Tools
More from this journal
Cancer collection based on different tumor types
Information for Authors
Cancer Communications offers waivers to authors for selected high quality articles. For rapid feedback on the potential suitability of an article for waiver, please send a pre-submission enquiry to the editorial office, providing the article title, abstract and a brief cover letter.
Impact Factors in Journal Citation Report (2018, Clarivate) are under the previous journal title Chinese Journal of Cancer.
Archival Content
To browse articles published in the journal prior to March 2015, please visit the Sun Yat-sen University Cancer Center website.
Understanding Open Access
As an open access journal, all articles in Cancer Communications are freely available to read, download and share immediately on publication.
Relevant Open – Access Health Sciences journals
Aging AND Cancer (2020-Present)
Cancer Innovation (2022-Present)
Clinical and Translational Medicine (2012-Present)
MedComm (2020-Present)
MedComm – Oncology (2022-Present)